Nextech Invest

Joined Nextech Ventures (US) in March 2023. Previously spent 11 years at BVF Partners managing growth from hundreds of millions to several billion under management, starting as analyst and promoted to managing director.

Partner with 30+ years of investment experience across multiple regions, joined Nextech in 2016. Previously spent two decades at AIG and was Asia chief executive of its wealth management business.

Oncology-focused investor who has been with Nextech since 2012, specializing in precision medicines and targeted therapies. Holds multiple current and past board seats at publicly traded and private biotech companies.

Chair of Department of Medical Oncology and Chief of Strategic Partnerships at Dana-Farber Cancer Institute, leading over 300 faculty members. Previously VP and Global Head of Translational Clinical Oncology at Novartis.

Professor at UCLA and director of tumor immunology program, president of AACR, and elected member of American Society of Clinical Investigation with recognition for research in tumor immunology.

Professor and co-chair of the Department of Molecular Medicine at Scripps Research Institute, member of the National Academy of Sciences, and scientific advisor to multiple biotech companies.

Director of the Department of Molecular Machines and Signaling at Max Planck Institute of Biochemistry, member of American Academy of Arts and Sciences and National Academy of Sciences.

Chair of Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center, past president of American Society of Clinical Investigation, and member of Institute of Medicine and National Academy of Sciences.

Founding chairman of Nextech's Scientific Advisory Board who passed away in October 2021. Served the firm for 15 years and was recognized as a giant in cancer research with nearly 50 years as a professor.

Professor and Chair of Department of Cancer Immunology and Virology at Dana-Farber Cancer Institute and Professor of Neurology at Harvard Medical School, focused on cytotoxic T cell discovery for cancer immunotherapies.

Professor of pharmaceutical sciences at ETH Zurich with extensive experience in chemistry and drug discovery leadership at Novartis, serving as global head of Discovery Chemistry and senior scientific expert.

Director of the Henri and Belinda Termeer Center for Targeted Therapies at Mass General Cancer Center and associate professor at Harvard Medical School with expertise in melanoma and targeted therapies.

Professor and Chair at UCSF Department of Cellular and Molecular Pharmacology, Howard Hughes Medical Institute investigator, and elected to National Academy of Sciences. Scientific co-founder of multiple biotech companies.

Scientist with passion for emerging cancer technologies, joined Nextech in 2019. Previously senior associate at Third Rock Ventures focused on scientific due diligence and new company formation in oncology and immunology.

Harrap Professor of Pharmacology at Institute of Cancer Research London, former CEO and President, Fellow of Royal Society, with expertise in molecular pharmacology of targeted cancer drugs and biomarker-led drug discovery.

Head of the Program in Immunology at Fred Hutchinson Cancer Research Center and professor at University of Washington, recognized leader in cancer immunology and scientific co-founder of Juno Therapeutics.

Scientist and entrepreneur with 25+ years in biotech, co-founder and chairman of ORIC Pharmaceuticals, and recently chaired Vividion Therapeutics and Amunix Pharma prior to their acquisitions by Bayer and Sanofi.

Professor at Dana-Farber Cancer Institute and Harvard Medical School, member of national advisory boards, and serves on the board of directors of Eli Lilly and the American Association for Cancer Research.

Joined Nextech as intern in 2019, transitioned to associate in 2021 and promoted to principal in 2025. Holds biotechnology degrees from ETH Zurich with master thesis in synthetic biology.

Joined Nextech in September 2024. Previously senior director of corporate development at Gilead Sciences executing multiple transactions. Holds degrees in biomedical engineering and PhD in bioengineering.

Joined Nextech in 2024 as executive assistant in Zurich office. Completed studies in business administration with experience as teaching assistant and receptionist at Cambridge Institute.

Joined Nextech in 2026 as head of investor relations. Brings experience from senior IR roles at Novartis, Roche, and Ipsen, plus equity research at investment banks. PhD in biomedical engineering from ETH Zurich.

Joined Nextech as executive assistant in San Francisco Bay Area. Previously supported executives in private equity and investment banking, managing operations and planning key leadership events.

Joined Nextech in 2025, based in Boston office managing finance and operations for US entity. Previously led finance at early-stage SaaS startup and worked in legal operations at Boston law firm.

Joined Nextech in September 2023 as associate in Zurich office. Spent 5 years in transaction services, M&A, and private equity in Paris and Zurich. Holds advanced master's in finance.

Joined Nextech as executive assistant in Boston office. Previously worked as child life program coordinator at Boston Children's Hospital on oncology and hematology floors.

Chief financial officer at Nextech since 2015. Previously served as CFO at vision4health group and held financial leadership roles at major pharmaceutical companies including Wyeth and Pfizer.

Joined Nextech in 2022 as financial controller overseeing finance operations for Swiss and US entities. Previously consultant at Big4 firm with experience in multinational controlling department.

Joined Nextech in 2026 as financial and accounting specialist in Zurich office. Previously held senior finance roles at ABB, Squirro, and X-Bionic with expertise in accounting and treasury management.

Joined Nextech in March 2025 as analyst. PhD in biochemistry and cell biology from Boston University with expertise in GPCR signaling and publications in high-impact journals.

Over 20 years in private markets across private equity, debt, infrastructure, and real estate. Member of executive committee at Patrimonium and previously CEO of Schroder Adveq and global head of private equity at Robeco Group.

Global chairman of investment banking at J.P. Morgan since 1991, focused on healthcare. Previously co-head of global healthcare investment banking and holds leadership positions on multiple academic and nonprofit boards.

Joined Nextech in 2024. Previously worked at Novartis Biomedical Research on covalent drug discovery in oncology and immunology. Postdoctoral researcher at University of Cambridge with multiple fellowship awards.